Recently, two cetuximab-decorated gelatin-based KRASG12C-specific siRNA delivery systems showing successful KRAS oncogene knockdown leading to sensitization of the cancer cells to gefitinib were described in the literature. The gene discussed is KRAS; the disease is cancer.